Cutaneous T-cell lymphoma patient-derived xenografts retain molecular characteristics across passages

Caroline Snowden(Northwestern University), Jaehyuk Choi(Northwestern University), Kimberly G. Ringbloom(Northwestern University), Weiyun Z. Ai(City College of San Francisco), Chi-Heng Wu(National Taiwan University), Katie Lee(Northwestern University)

European Journal of Cancer

October 1, 2021

10.1016/s0959-8049(21)00696-1

Cited by 0

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

|Journal of Clinical Oncology|2010|487

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

|Journal for ImmunoTherapy of Cancer|2018|468

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

|The Lancet Oncology|2021|428

Genomic landscape of cutaneous T cell lymphoma

|Nature Genetics|2015|418